Leading the Way in Life Science Technologies

GEN Exclusives

More »

Wall Street BioBeat

More »
Nov 1, 2010 (Vol. 30, No. 19)

Biotech Posts Strong Third-Quarter Results

Robust Performance Hailed as Strongest September Rally in More than 70 Years

  • IP Queue

    In addition to these two biofuel companies, several other biotechs filed to add themselves to the IPO queue in the quarter including:

    • Complete Genomics (www.completegenomics.com), has already sequenced more than 200 complete human genomes since the beginning of the year, according to its filing.
    • Horizon Pharma (www.horizonpharma.com), has a product on the market in Europe. Lodotra is a low-dose formulation of prednisone, for the treatment of rheumatoid arthritis.
    • Aegerion Pharmaceuticals (www.aegerion.com) is focused on the development and commercialization of pharmaceuticals to treat cardiovascular and metabolic diseases.
    • Cutanea Life Sciences (www.cutanealife.com) is a development-stage specialty pharmaceutical company whose mission is to strategically in-license novel, mid-stage candidates to treat diseased and aging skin conditions.
    • Endocyte (www.endocyte.com) is developing targeted therapies for the treatment of cancer and other serious diseases.
    • Pacific Biosciences (www.pacificbiosciences.com) has developed a single molecule, real-time technology that enables analysis of biomolecules with single-molecule resolution.
  • Public Company Financings Soft

    Analysis in the Burrill Report shows that, apart from debt financings, all other financing vehicles were down a collective 50%, compared with the second quarter of 2010.

    Follow-on financing and IPOs were down quarter-over-quarter; however, padding the data was the $7.2 billion raised in debt financing, bringing the total raised in the third quarter to $9.5 billion.

    Venture capital financing continued to flow to U.S. biotech companies with $1.3 billion raised from about 90 deals announced in the third quarter. The U.S. biotech industry is on track to raise over $20 billion by the end of the year.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »